We can't wait to see the 2019 ‘Agents of Change’ AD Challenge grant recipients help make a difference in the #AtopicDermatitis community. Learn more about the challenge at https://t.co/COlsGghdzX pic.twitter.com/p7wX6WDwFt
— Sanofi (@sanofi) August 5, 2020
The #COVID19 pandemic has had a considerable impact on all patients, whether directly affected by coronavirus or not. Read more about the challenges #cancer patients have faced:https://t.co/gl0AH4h1uV pic.twitter.com/QUjru22IE1
— Sanofi (@sanofi) August 4, 2020
Last week we announced #COVID19 vaccine supply agreements with the UK & US governments.
In partnership with @GSK, we are working to develop a safe & effective vaccine and make it available to everyone as quickly as possible.https://t.co/mhBxKJPYxV #SanofiActs pic.twitter.com/MAMlzJxSMq— Sanofi (@sanofi) August 3, 2020
Today we welcome Natalie Bickford @natbickford on her first day as Chief People Officer at Sanofi. She brings a wealth of HR leadership experience, and a strong track record of transforming organizations, with a strong focus on inclusion and diversity. https://t.co/MKRYUsUW6Z pic.twitter.com/KeBvAc4QJS
— Sanofi (@sanofi) August 3, 2020
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection in infants and young children. #DYK the US discussed the term #RSV more than any other country on the internet? Learn more about the worldwide fluctuation.https://t.co/G9Wzw9qmhn
— Sanofi (@sanofi) August 3, 2020
Thomas Triomphe, EVP @SanofiPasteur, on our cooperation with @GSK and the @EU_Commission: “Today’s announcement helps to ensure that millions of Europeans will have access to a potential vaccine protecting against COVID-19, once proven safe and effective.”https://t.co/dI8dgN4Rxp
— Sanofi (@sanofi) July 31, 2020
Collaborating with @HHSGov and @DeptofDefense will help fund the development and manufacturing of Sanofi’s and @GSK’s recombinant protein-based vaccine, resulting in a significant increase in capacity:https://t.co/IB99LosxZ7#SanofiActs pic.twitter.com/DGoDq8L8y8
— Sanofi (@sanofi) July 31, 2020
Just published: Data from a Phase IIb trial in the @NEJM show positive results of an investigational preventative #RSV immunization. Learn more: https://t.co/SCSgQc9B0o pic.twitter.com/7rRXCiv6Un
— Sanofi (@sanofi) July 30, 2020
[#SanofiResults] Today we announced our Q2 2020 financial results.
Our CEO Paul Hudson credits our teams for a strong first half of 2020, even in challenging times. https://t.co/oMsnzqGGyi $SAN $SNY pic.twitter.com/ODT11Dicuo— Sanofi (@sanofi) July 29, 2020
[#SanofiResults] Our Q2 2020 Financial Results are now available. Read the press release: https://t.co/mg15LxP5Wb $SAN $SNY pic.twitter.com/QRe0AF8JUY
— Sanofi (@sanofi) July 29, 2020
Read Olivier Charmeil’s article on the need to find new approaches to better manage chronic diseases and stay tuned for an upcoming series of conversations exploring new pathways in healthcare. https://t.co/slEnmz82d8
— Sanofi (@sanofi) July 28, 2020
To #FightCOVID19, Sanofi is working with 2 different technologies: a recombinant protein technology and mRNA technology. https://t.co/667HvaBLFJ#SanofiActs pic.twitter.com/b6gXa5g1iV
— Sanofi (@sanofi) July 28, 2020
At Sanofi, we are truly putting #ScienceFirst and thinking long term. Read more about the latest partnerships in our #RD strategy:
— Sanofi (@sanofi) July 27, 2020
“It’s more important than ever for people to understand better what #vaccines are and how they work.” Thomas Triomphe, Executive Vice President @SanofiPasteur.
Learn more about how #vaccineswork in the first episode of our new series The Upshot: https://t.co/667HvaTn4j— Sanofi (@sanofi) July 27, 2020
#COVID19 has highlighted the importance of self-care. To mark International Self-Care Day, Carol-Ann Stewart, Head of Consumer Healthcare, Sanofi Latin America, discusses how people are shifting their attitudes towards preventative wellnesshttps://t.co/TtXy9umR40#SelfCareForAll
— Sanofi (@sanofi) July 24, 2020
What are multi-specific #antibodies, and how can they be used against diseases like cancer and immunological disorders?
Find out in this 2-minute overview: pic.twitter.com/ozAly9LCLg— Sanofi (@sanofi) July 22, 2020
Achieving this #ScienceBasedTarget will be a team effort with all our employees as well as our partners and suppliers. We are committed to contributing to this global effort. https://t.co/7TjwDvwkN3
— Sanofi (@sanofi) July 20, 2020
Sanofi participated in an international campaign to alert young people about the risks of #FakeMeds #RelyOnYouth. Criminals always take advantage of a pandemic like #COVID19 by proposing illicit medicines on the Internet. pic.twitter.com/LvWO7oZlu6
— Sanofi (@sanofi) July 17, 2020
Following the #COVID19 pandemic, "the entire healthcare ecosystem evolved to be faster, more collaborative, and more innovative." Read Sanofi CEO Paul Hudson’s article in @FortuneMagazine on the lessons we can draw from the crisis https://t.co/iiBoqkZeny
— Sanofi (@sanofi) July 16, 2020
Sanofi scientists are breaking barriers in hemophilia research, exploring extended half-life factor replacement therapy, rebalancing RNAi therapy, and gene therapies. What makes our approach unique? #ISTH2020 https://t.co/yIl6kmVKdD
— Sanofi (@sanofi) July 13, 2020
Through our multi program strategic partnership with @KymeraTx, we aim to advance novel protein degrader therapies to patients with immune-inflammatory diseases. #Immunotherapy https://t.co/obvL4ju3zt pic.twitter.com/ZR5ABqgbmv
— Sanofi (@sanofi) July 10, 2020
Voices from the Lab: hear from Ercole Rao, Section Head Biologics Research at @sanofiDE, on his team's work on multi-specific antibodies to try to "cure the incurable". #researchers #immunotherapy
Filmed in November 2019 pic.twitter.com/wrfkYcrFWg
— Sanofi (@sanofi) July 9, 2020
To further develop treatment combinations for patients with multiple myeloma, Sanofi is working with @KiadisPharma to license a cell therapy that we will be studying with our recently FDA-approved treatment. https://t.co/iG9EVTz4OM#mmsm #Immunotherapy pic.twitter.com/Df7evqvsH8
— Sanofi (@sanofi) July 9, 2020
At Sanofi, we are committed to reducing the impact of our operations on the environment – from the raw materials we use in our products to their potential end-of-life impact.
Learn more about our strategy for 2015-2025: https://t.co/dI4Hd9tmEE#ScienceBasedTargets— Sanofi (@sanofi) July 8, 2020
#DYK that more than 90% of online pharmacies are likely illicit? Before buying medicines online, Sanofi shares some tips to protect yourself from #FakeMeds. https://t.co/5LwaV1tWm6 #Protectyourself pic.twitter.com/2pXdKJpwfq
— Sanofi (@sanofi) July 7, 2020
As the @WHO announces the number of reported cases of #sleepingsickness for 2019, Sanofi continues to work towards the goal of eliminating this disease as a public health issue by the end of 2020. #BeatNTDs
— Sanofi (@sanofi) July 3, 2020
World #Allergy Week (June 28 – July 4)
How to manage respiratory allergies during the #COVID19 pandemic? @worldallergy shares the recommendations for patients affected by respiratory allergies. https://t.co/XMi2ApJVKA pic.twitter.com/dZI0xl2trB— Sanofi (@sanofi) July 1, 2020
Since #COVID19 emerged, Sanofi has fought the pandemic on all sides. In this video, discover how #SanofiActs in the pursuit of a vaccine: https://t.co/QGx2QZpOXX pic.twitter.com/IYW2W1f9Kq
— Sanofi (@sanofi) June 24, 2020
Our CEO Paul Hudson discusses Sanofi #RD strategy: "Faced with a pandemic, we have made tremendous progress on our pipeline and are even closer to delivering breakthroughs for patients." https://t.co/3aMzTzvJ4C
— Sanofi (@sanofi) June 24, 2020
What is the Expanded Genetic Alphabet, and how can it help us improve treatments for patients with #cancer? Listen to our podcast to know more. pic.twitter.com/WXTdtd1KyA
— Sanofi (@sanofi) June 23, 2020
Today we will share long-term interim data in a late-breaking session at #WFHVirtualSummit from our Phase 2 study investigating a potential RNAi treatment for #hemophilia A and B, with or without inhibitors. https://t.co/lKeElnoMxt pic.twitter.com/uWfJyjjEc6
— Sanofi (@sanofi) June 19, 2020
Our medicine is now approved in China for the treatment of moderate-to-severe #atopicdermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. cc @Regeneron Read the news: https://t.co/AqapsBLSYZ pic.twitter.com/unLRSgPqhu
— Sanofi (@sanofi) June 19, 2020
Through research we commissioned with @EIUPerspectives in the US, Japan and Europe, gaps have been uncovered in #cancer care for the aging, and the impact those gaps can have on healthcare systems. Find out more. #WhenCancerGrowsOld
— Sanofi (@sanofi) June 18, 2020
What do llamas have to do with drug development? Find out how their Nanobodies®, or miniature antibodies, are helping us develop new medicines: pic.twitter.com/QTiRIOCPxQ
— Sanofi (@sanofi) June 18, 2020
In our new blog post on The Next Breath, we hear from our own Dr. Paul Rowe and @Regeneron’s Dr. Yamo Deniz about the importance of patients getting involved in research to advocate for their care. Check out the full interview. https://t.co/YBj7Ve5K6I
— Sanofi (@sanofi) June 18, 2020
#AtopicDermatitis (AD) can place a burden on the entire family, especially parents and caregivers. With @Regeneron, we are here to educate about the impacts of this chronic skin disease and to #ChangeAD. Visit https://t.co/LoPcFjaDIp to learn more. pic.twitter.com/Ow46opVYUQ
— Sanofi (@sanofi) June 17, 2020
Developed by Sanofi in partnership with @DNDi, the treatment for #SleepingSickness has been donated to the @WHO for distribution and will play a key role in achieving the elimination of the disease by 2020.#NTDs #BeatNTDshttps://t.co/MShOmUJRGt pic.twitter.com/IxOOELaVlu
— Sanofi (@sanofi) June 17, 2020
Always focused on adding more strings to her bow, Tiffany is a talented makeup artist, actress, film producer & musician. It’s not always easy, but she doesn’t let #Pompe disease stop her from pursuing her dreams. pic.twitter.com/yhc4WFpN9Y
— Sanofi (@sanofi) June 16, 2020
Today, we presented Phase 3 study results evaluating our investigational enzyme replacement therapy for people with late-onset #Pompe disease. https://t.co/2FfETYkvyR pic.twitter.com/l8rCJMJ8m4
— Sanofi (@sanofi) June 16, 2020
We announced today major investments in a state-of-the art production site and a new research center both dedicated to vaccines. These investments will make France our world class center of excellence in vaccine research and production. https://t.co/F9O4lFQL2Z
— Sanofi (@sanofi) June 16, 2020
Research on #LungCancer has led to important discoveries and advances. Learn more about how a protein called CEACAM5 may hold the key to a new approach to lung cancer treatment: https://t.co/mcqCzFEYGM #cancerresearch
— Sanofi (@sanofi) June 16, 2020
Sanofi to present growth opportunities and development strategy for investigational indications across type 2 inflammatory diseases including #dermatology, #respiratory and #eosinophilicesophagitis https://t.co/9dfsmgEtHP
— Sanofi (@sanofi) June 11, 2020
While Sanofi continues pursuing solutions for #COVID19, it recognizes the urgency of carrying on the work of building a healthier environment. On this #WorldEnvironmentDay, find out how #SanofiActs to create a healthier future: https://t.co/9QPxmeJX9l pic.twitter.com/sh2JnNXp3s
— Sanofi (@sanofi) June 5, 2020
With @Regeneron, we’re sharing data at #EAACI2020 that can help advance knowledge in allergic and respiratory diseases. Check out our presentations on type 2 inflammatory diseases like #asthma, #nasalpolyps and #atopicdermatitis. pic.twitter.com/X6wewALG49
— Sanofi (@sanofi) June 4, 2020
We are proud to be featured in @IAmBiotech @BIOConvention’s new #BeyondImagination series at #BIODigital for our work fighting #COVID19. https://t.co/hPnIJ41m5y
— Sanofi (@sanofi) June 4, 2020
"#COVID19 forces us to reckon with the compounding impact of the uncontrolled epidemic of chronic diseases." Read Olivier Charmeil’s article on the need to rethink our response to fighting chronic diseases: https://t.co/EOmg8NmfJ2
— Sanofi (@sanofi) June 2, 2020
The @EU_Commission granted marketing authorization for our treatment for certain adult patients with relapsed and refractory #multiplemyeloma, reaching another important milestone for #Sanofi. Learn more: https://t.co/n6cXoVzRIl #mmsm
— Sanofi (@sanofi) June 2, 2020
We are committed to leading the way in the development of innovative treatments and continue to identify selective targets for cancer, one of which is an investigational #BreastCancer compound: https://t.co/YRXogIUCrr pic.twitter.com/pnisnF9fkq
— Sanofi (@sanofi) June 1, 2020
Have you experienced challenges when treating aging patients with #cancer? Hear from expert oncologists Drs. Aapro and Brain as they share their POV on the obstacles they’ve faced when treating this population. #ASCO20
— Sanofi (@sanofi) May 29, 2020
Today, we announced longer-term data from our pivotal Phase 2 trial in advanced Cutaneous #SquamousCellCarcinoma (CSCC) with @Regeneron #ASCO20: https://t.co/rnOUU37fzv pic.twitter.com/N9kijVlnB5
— Sanofi (@sanofi) May 29, 2020
Many people around the world are spending more time indoors and sometimes might overlook their digestive health. On this #WDHD2020, Sanofi invites people to discover, learn and act to take care of their digestive system. #GutMicrobiome https://t.co/EnxPDxj6b0 pic.twitter.com/6M58Rezgqi
— Sanofi (@sanofi) May 29, 2020
Our Global Head of Oncology Development & Pediatric Innovation Dr. Peter Adamson reflects on the “new normal” of a virtual #ASCO20 and the key themes he’s watching. #cancerresearch Read here: https://t.co/tOholZYXcM pic.twitter.com/100QRGwLzR
— Sanofi (@sanofi) May 28, 2020
Asim Jamal, Country Lead, @SanofiPK, discusses the impact of #COVID19 on his team and their everyday work: "I soon began to notice that the team was bonding better."
Watch our series on the #LessonsLearned since the COVID19 pandemic emerged. pic.twitter.com/IvjEIUBts4
— Sanofi (@sanofi) May 25, 2020
#Sanofi and @Regeneron announce positive results from our trial in adults and adolescents with #EosinophilicEsophagitis. https://t.co/2Su4FYK1cZ
— Sanofi (@sanofi) May 22, 2020
Did you know #ClinicalTrials started as very humble research more than 270 years ago? Today, they are key in bringing new treatments and vaccines to people. But how do they work? https://t.co/h3w8cwrGGJ #CTD2020 pic.twitter.com/OME4mSNC8b
— Sanofi (@sanofi) May 20, 2020
This week, John Reed, Sanofi Global Head of R&D, participated in @CNBCNews #HealthyReturns Virtual Summit. Watch the full session about how the #COVID19 pandemic led to unprecedented industry partnerships. https://t.co/Ew3QP9IM7G
— Sanofi (@sanofi) May 15, 2020
In the last week of April, as the world raced to #FightCOVID19, our teams in India, France and Germany were fighting another battle. Discover how our courageous employees responded to provide solutions to those who need it most. pic.twitter.com/NMcTUGyccJ
— Sanofi (@sanofi) May 12, 2020
#SanofiActs Sanofi carries on
Today, we announced our Phase 3 clinical trial met its primary endpoint early in certain adult patients with relapsed #multiplemyeloma. Read more about the study here: https://t.co/BhiICTQ7QX #mmsm— Sanofi (@sanofi) May 12, 2020
#SanofiActs
Following the #COVID19 pandemic, all Sanofi's facilities had to adapt. At Ambarès (France), a crisis center has rapidly been set up to maintain the production line while protecting our employees' health. pic.twitter.com/SvfWS05HPa— Sanofi (@sanofi) May 11, 2020
On International Self-Care Day, Alan Main, GSCF Chairman, talks about #selfcare as a vital foundation of global health systems. #SelfCareForAll👇 pic.twitter.com/nzWEXHYRwb
— The Global Self-Care Federation (@Selfcarefed_org) July 24, 2020
https://twitter.com/Selfcarefed_org/status/1285153106175680513
https://twitter.com/Selfcarefed_org/status/1260827281620164609
"We hope to be ready for patients before the summer of next year, first half of 2021 … people forget sometimes we're the only proven platform that's out there to treat #COVID19," Sanofi CEO Paul Hudson shares vaccine progress ahead of Sanofi's R&D day. pic.twitter.com/YuVI5DCCte
— Squawk Box (@SquawkCNBC) June 23, 2020
Amit’s severe #asthma diagnosis disrupted her life initially. But by learning more about her disease, she was able to take control. Learn more about severe asthma and its causes. https://t.co/C2M3mj04U8 pic.twitter.com/FlFU7tVfAD
— Sanofi Genzyme (@SanofiGenzyme) June 22, 2020
Through our commitment to the @WFHemophilia Humanitarian Aid Program, a sustainable & predictable supply of clotting factor has allowed for the introduction of life-changing prophylactic therapy for approximately 1,400 people, primarily children. pic.twitter.com/N7q2tIr5Zy
— Sanofi Genzyme (@SanofiGenzyme) June 16, 2020
With Sobi, our commitment to the WFH Humanitarian Aid Program has had a far-reaching impact in the developing world. We're proud to donate up to 500 million additional IUs of clotting factor, fulfilling the 2014 pledge to donate up to 1 billion IUs for humanitarian use.
— Sanofi Genzyme (@SanofiGenzyme) June 15, 2020
To tackle #COVID19 we’ve joined forces with @GSK to develop a vaccine and partner with governments and organizations to make it globally available.
Discover more here: https://t.co/rLgcmhu1My #SanofiActs https://t.co/EE3pQZHUHg
— Sanofi Pasteur (@sanofipasteur) August 4, 2020
Childhood vaccination is a crucial part of keeping populations healthy, but uptake is slowing according to @WHO & @UNICEF.
Even during the #COVID19 pandemic, it’s vital that we continue to safeguard routine immunization #vaccineswork https://t.co/lKefDv2HCZ
— Sanofi Pasteur (@sanofipasteur) July 16, 2020
We’re proud to be working in partnership with @GSK, sharing expertise in order to drive COVID-19 vaccine discovery. We’re doing everything we can to be a part of the solution. #WeWontRest https://t.co/u7hOZI8dfn
— Sanofi Pasteur (@sanofipasteur) June 9, 2020
As @Gavi marks its 20th anniversary, we reaffirm our commitment to #ProtectTheNextGeneration from serious infectious diseases, including polio. Read more @IFPMA https://t.co/gDLB2moOrf #GenerationGavi #GVS2020 pic.twitter.com/2FmWjNF9sR
— Sanofi Pasteur (@sanofipasteur) June 4, 2020
Our new collaboration with MD Anderson Cancer Center will help scientists explore new drug combinations and potential new indications for existing #medicines. Learn more: https://t.co/RJd9QGIVwJ @MDAndersonNews pic.twitter.com/0Ref2lXpmk
— Sanofi US (@SanofiUS) July 14, 2020
Sanofi is at the forefront of unprecedented industry collaboration to fight #COVID19. Bill Sibold, President, Sanofi North America discusses the important work we’re doing with @GlobalBiz. Watch here: https://t.co/RPDNO0RpkG pic.twitter.com/UJaNu5KMhs
— Sanofi US (@SanofiUS) July 13, 2020